Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Saurabh ZanwarMatthew HoPrashant KapoorAngela DispenzieriMartha Q LacyMorie A GertzFrancis K BuadiSuzanne R HaymanDavid DingliTaxiarchis V KourelisAmie FonderMiriam HobbsYi HwaWilson GonsalvesRahma WarsameEli MuchtarNelson R LeungRobert A KyleS Vincent RajkumarShaji K KumarPublished in: Leukemia (2021)